Discover
BBOT
BridgeBio Oncology Therapeutics, Inc.
7.80
2 x 5.75
2 x 9.80
bid
ask
+
0.18
2.36%
2 @ 04:00 PM
7.80 +0.00 (0.00%)
| Ytd | -37.70% | |
| 1y | -26.69% |
7.58
day range
8.08
7.00
52 week range
14.87
| Open | 7.62 | Prev Close | 7.62 | Low | 7.58 | High | 8.08 | Mkt Cap | 624.84M |
| Vol | 479.24K | Avg Vol | 462.99K | EPS | -1.92 | P/E | N/A | Forward P/E | N/A |
| Beta | N/A | Short Ratio | 4.43 | Inst. Own | 52.88% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 8.18 | 200-d Avg | 10.45 | 1yr Est | 24.20 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-02-11 | 2025-12 | 0 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2025-11-13 | Oppenheimer | Upgrade | Outperform | Outperform |
| 2025-09-17 | Leerink Partners | Upgrade | Outperform | |
| 2025-09-15 | HC Wainwright & Co. | Upgrade | Buy | |
| 2025-09-04 | Oppenheimer | Upgrade | Outperform | |
| 2025-08-18 | Wedbush | Upgrade | Outperform |
Profile
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics targeting renin-angiotensin system and phosphoinositide 3-kinase malignancies. The company's product pipeline includes BBO-8520, a direct inhibitor targeting the on and off states of KRAS that is in Phase I clinical trial to treat patients with KRASG12C mutant non-small cell lung cancer; and BBO-10203, an orally bioavailable small molecule that is in Phase I clinical trial for treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS pancreatic ductal adenocarcinoma (PDAC), KRAS mutant colorectal cancer (CRC), and KRAS mutant NSCLC. It is also developing BBO-11818, an orally bioavailable pan KRAS on/off inhibitor that is in Phase I clinical trial to treat patients with KRASG12D and KRASG12V mutant NSCLC, PDAC, and CRC. The company was founded in 2016 is headquartered in South San Francisco, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2025-08-10 | CHEN BIHUA X. | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Stock Award(Grant) |
| 2024-02-12 | HELIX HOLDINGS II L.L.C. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Stock Award(Grant) |
| 2025-08-10 | HOLMAN ALBERT A III | Former | 30.00K | Conversion of Exercise of derivative security |
| 2025-08-10 | MCKENNA MARK C | Former | 30.00K | Conversion of Exercise of derivative security |
| 2025-08-10 | SCHMID JOHN P | Former | 30.00K | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-09-29 | Alphabet Inc. | 2.82M | 34.95M | 3.56% |
| 2025-09-29 | Blackrock Inc. | 2.05M | 25.36M | 2.59% |
| 2025-09-29 | Vanguard Group Inc | 647.60K | 8.02M | 0.82% |
| 2025-09-29 | Aisling Capital Management LP | 564.63K | 6.99M | 0.71% |
| 2025-09-29 | Geode Capital Management, LLC | 541.60K | 6.71M | 0.68% |
| 2025-09-29 | SilverArc Capital Management, LLC | 457.41K | 5.66M | 0.58% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-08-30 | BlackRock Funds-BLACKROCK HEALTH SCIENCES OPPORTUNITIES PORTFOLIO | 841.29K | 10.42M | 1.06% |
| 2025-09-29 | Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 251.29K | 3.11M | 0.32% |
| 2025-09-29 | Fidelity Select Portfolios-Select Biotechnology Portfolio | 134.68K | 1.67M | 0.17% |
| 2025-09-29 | Fidelity Concord Street Trust-Fidelity Total Market Index Fund | 91.18K | 1.13M | 0.12% |
| 2025-09-29 | Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund | 68.32K | 845.74K | 0.09% |
| 2025-09-29 | Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 48.35K | 598.59K | 0.06% |